Liver-Gut-Interaction: Role of Microbiome Transplantation in the Future Treatment of Metabolic Disease

The association between shifts in gut microbiome composition and metabolic disorders is a well-recognized phenomenon. Clinical studies and experimental data suggest a causal relationship, making the gut microbiome an attractive therapeutic goal. Fecal microbiome transplantation (FMT) is a method to...

Full description

Saved in:
Bibliographic Details
Published in:Journal of personalized medicine 2023-01, Vol.13 (2), p.220
Main Author: Stadlbauer, Vanessa
Format: Article
Language:English
Subjects:
Bacteria
Cancer
Diet
Disease
DNA methylation
Drug therapy
Feces
Gastrointestinal surgery
Health aspects
Infections
Insulin resistance
Intestinal microflora
Liver
Medical research
Medical screening
Medicine, Experimental
Metabolic disorders
Metabolic syndrome
Metabolites
Microbiomes
Microbiota
Microorganisms
Obesity
Precision medicine
Probiotics
Transplantation
Transplants & implants
Type 2 diabetes
Veganism
Weight control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The association between shifts in gut microbiome composition and metabolic disorders is a well-recognized phenomenon. Clinical studies and experimental data suggest a causal relationship, making the gut microbiome an attractive therapeutic goal. Fecal microbiome transplantation (FMT) is a method to alter a person's microbiome composition. Although this method allowed for the establishment of proof of concept for using microbiome modulation to treat metabolic disorders, the method is not yet ready for broad application. It is a resource-intensive method that also carries some procedural risks and whose effects are not always reproducible. This review summarizes the current knowledge on FMT to treat metabolic diseases and gives an outlook on open research questions. Further research is undoubtedly required to find applications that are less resource-intensive, such as oral encapsulated formulations, and have strong and predictable results. Furthermore, a clear commitment from all stakeholders is necessary to move forward in the direction of developing live microbial agents, next-generation probiotics, and targeted dietary interventions.
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm13020220